Quick Answer
Edesa Biotech, Inc. reported Total Revenue of $0.00 for fiscal year 2021.
Edesa Biotech, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | $0.00 -100.0% |
$328.8K |
| Net Income | -$7.19M -16.5% |
-$6.17M +26.3% |
-$8.37M +52.3% |
-$17.55M -31.5% |
-$13.34M -109.7% |
-$6.36M |
| Diluted EPS | — | — | — | — | — | — |
| Total Assets | $13.53M +254.8% |
$3.81M -57.1% |
$8.89M -23.2% |
$11.58M -20.6% |
$14.58M +35.5% |
$10.76M +88.2% |
| Cash and Equivalents | — | — | — | $7.09M -9.5% |
$7.84M +8.7% |
$7.21M +43.4% |
| Stockholders Equity | $12.45M +528.5% |
$1.98M -71.9% |
$7.05M -24.9% |
$9.39M -28.1% |
$13.06M +96.9% |
$6.63M +26.2% |
| R&D Expense | $3.67M +27.3% |
$2.88M -39.9% |
$4.79M -64.0% |
$13.34M -25.7% |
$17.95M +439.0% |
$3.33M |
| Operating Income | -$7.91M -12.8% |
-$7.01M +23.9% |
-$9.22M +49.8% |
-$18.37M +22.4% |
-$23.68M -270.0% |
-$6.40M |
| Shares Outstanding | 7.14M +119.9% |
3.25M +5.6% |
3.08M +29.2% |
2.38M -82.1% |
13.30M +38.3% |
9.62M +28.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2021 | $0.00 | -100.0% | — |
| Net Income | December 31, 2025 | -$2.25M | -39.0% | -28.5% |
| Diluted EPS | June 30, 2016 | -$0.14 | -380.0% | -380.0% |
| Total Assets | December 31, 2025 | $14.71M | +253.3% | +8.7% |
| Cash and Equivalents | June 30, 2023 | $6.46M | -49.6% | -13.6% |
| Stockholders Equity | December 31, 2025 | $13.95M | +516.4% | +12.1% |
| R&D Expense | December 31, 2025 | $1.12M | +10.3% | +19.8% |
| Operating Income | December 31, 2025 | -$2.34M | -23.3% | -23.0% |
| Shares Outstanding | December 31, 2025 | 8.33M | +140.3% | +16.7% |
- Edesa Biotech, Inc. reported Total Revenue of $0.00 for fiscal year 2021.
- Edesa Biotech, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Edesa Biotech, Inc. reported Net Income of -$7.19 million for fiscal year 2025.
- Edesa Biotech, Inc. showed a decrease of -16.5% in Net Income compared to the prior fiscal year.
- Edesa Biotech, Inc. reported Diluted EPS of $0.57 per share (loss) for fiscal year 2016.
- Edesa Biotech, Inc. showed a decrease of -58.3% in Diluted EPS compared to the prior fiscal year.
- Edesa Biotech, Inc. reported Total Assets of $13.53 million for fiscal year 2025.
- Edesa Biotech, Inc. showed an increase of +254.8% in Total Assets compared to the prior fiscal year.
- Edesa Biotech, Inc. reported Cash and Equivalents of $7.09 million for fiscal year 2022.
- Edesa Biotech, Inc. showed a decrease of -9.5% in Cash and Equivalents compared to the prior fiscal year.
- Edesa Biotech, Inc. reported Stockholders Equity of $12.45 million for fiscal year 2025.
- Edesa Biotech, Inc. showed an increase of +528.5% in Stockholders Equity compared to the prior fiscal year.
- Edesa Biotech, Inc. reported R&D Expense of $3.67 million for fiscal year 2025.
- Edesa Biotech, Inc. showed an increase of +27.3% in R&D Expense compared to the prior fiscal year.
- Edesa Biotech, Inc. reported Operating Income of -$7.91 million for fiscal year 2025.
- Edesa Biotech, Inc. showed a decrease of -12.8% in Operating Income compared to the prior fiscal year.
- Edesa Biotech, Inc. reported Shares Outstanding of 7.14 million shares for fiscal year 2025.
- Edesa Biotech, Inc. showed an increase of +119.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: